SCHEMBL23319916

SCHEMBL23319916

CC(C)(C)c1ccc(-c2ccc(Oc3[nH]nnc3C(=O)O)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 2/20 0.42
DHODH Q02127 2/20 0.41
HAO1 Q9UJM8 2/20 0.39
FABP1 P07148 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
NR4A2 P43354 1/20 0.37
IKBKB O14920 1/20 0.37
RXRA P19793 1/20 0.37
RXRB P28702 1/20 0.37
BCL2 P10415 1/20 0.37
MDM2 Q00987 1/20 0.37
MCL1 Q07820 1/20 0.37
PRKAG1 P54619 1/20 0.37
PRKAA1 Q13131 1/20 0.37
PRKAB1 Q9Y478 1/20 0.37
NR1H4 Q96RI1 1/20 0.37
AKR1C2 P52895 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23319908 0.96 SMN1; SMN2 (0.42) XDHDHODHHAO1SMN1; SMN2MAPT
SCHEMBL25464977 0.90 HAO1 (0.38) XDHDHODHHAO1PRKAG1PRKAA1
SCHEMBL25464164 0.89 HAO1 (0.37) XDHDHODHHAO1PRKAG1PRKAA1
SCHEMBL21312598 0.87 KIF11 (0.44) DHODHHAO1
SCHEMBL21296847 0.85 PRKAG1 (0.51) XDHHAO1SMN1; SMN2MAPTMCL1
SCHEMBL21296970 0.85 ALPL (0.42) XDHDHODHHAO1MAPTPRKAG1
SCHEMBL21296854 0.85 HAO1 (0.44) HAO1MCL1PRKAG1PRKAA1PRKAB1
SCHEMBL23319995 0.82 HAO1 (0.46) HAO1PRKAG1PRKAA1PRKAB1
SCHEMBL23320006 0.82 HAO1 (0.46) HAO1PRKAG1PRKAA1PRKAB1
SCHEMBL21296959 0.82 MCL1 (0.46) HAO1SMN1; SMN2MCL1PRKAG1PRKAA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143491-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS PHOENIX TISSUE REPAIR, INC. 2023-05-11 US disclosed
US-20230143491-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS PHOENIX TISSUE REPAIR, INC. 2023-05-11 US disclosed
US-20230143491-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS PHOENIX TISSUE REPAIR, INC. 2023-05-11 US disclosed
US-20210403439-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS VENTHERA, INC. 2021-12-30 US disclosed
EP-3817816-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS Orfan Biotech Inc. (US) 2021-05-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143491-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS XDH, DUOX1, PNPO XDH 1/4885DHODH 82/4885HAO1 6/4885
US-20210403439-A1 TRIAZOLE GLYCOLATE OXIDASE INHIBITORS XDH, DUOX1, PNPO XDH 1/4885DHODH 82/4885HAO1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.